Sep 26, 2022
In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about novel agents in development for Major Depressive Disorder or MDD.
Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-MDD.
Learning Objectives: After completing this educational activity, you should be better able to:
Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.
Credit Types. The following are being offered for this activity:
Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.
Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented.
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA
Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva
Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva
Vladimir Maletic, MD, MS
Clinical Professor of Psychiatry, University of South Carolina School of Medicine, Greenville, SC
Consultant/Advisor: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Relmada, Sunovion, Supernus, Takeda
Speakers Bureau: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda
Sabrina K. Bradbury-Segal, PhD
Medical Writer, Neuroscience Education Institute, Carlsbad, CA
No financial relationships to disclose.
The Planning Committee and Peer Reviewer have no financial relationships to disclose.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout.
Support: This activity is supported by an unrestricted educational grant from Sage Therapeutics, Inc.
Released: September 26, 2022 CME/CE credit expires: September 26, 2025